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Prognostic Role of Serum Chloride Levels
in Acute Decompensated Heart Failure
Justin L. Grodin, MD, Jennifer Simon, BA, Rory Hachamovitch, MD, Yuping Wu, PHD, Gregory Jackson, MD,
Meghana Halkar, MD, Randall C. Starling, MD, MPH, Jeffrey M. Testani, MD, MTR, W.H. Wilson Tang, MD

H

eart failure (HF) is often complicated by

(3–5). The ﬁnding of hyponatremia in the patient with

electrolyte abnormalities. As ventricular

HF is a well-established, strong predictor of short- and

dysfunction progresses to symptomatic

long-term morbidity and mortality irrespective of left

HF, up-regulation of maladaptive neurohormonal sys-

ventricular (LV) systolic function (6–13).

tems may limit solute and free water delivery to the
distal nephron, increasing free water absorption and
potentially reducing serum sodium and chloride levels

However, the impact of hypochloremia in HF is less

(1,2). These electrolyte perturbations may be exacer-

well understood despite its broad availability in

bated through the use of decongestive therapies in

routinely used blood chemistry panels and its com-

acute and chronic HF (e.g., loop and thiazide diuretics)

mon attribution to contraction alkalosis during

ABBREVIATIONS

excessive decongestion therapy. Further-

Pennsylvania from 2004 to 2009 were reviewed. The

AND ACRONYMS

more, lower serum chloride levels relative to

assembly and characteristics of patients in this cohort

sodium levels may identify an electrolyte-

have been previously described (14,15). Brieﬂy, in-

deplete acute decompensated HF (ADHF)

clusion required a primary discharge diagnosis of

phenotype with different prognostic conse-

congestive HF, a hospital admission length between

quences. This study aimed to determine the

3 and 14 days, and a B-type natriuretic peptide level

independent

long-term

>100 pg/ml within 24 h of admission. Patients on

prognostic impact of admission serum chlo-

renal-replacement therapy were excluded from anal-

ride levels after hospitalization for ADHF.

ysis, as were patients without documentation of

METHODS

speciﬁc HF etiology, available blood chemistry values

ADHF = acute decompensated
heart failure

CI = conﬁdence interval
HF = heart failure
HR = hazard ratio
ICD = implantable
cardioverter-deﬁbrillator

LV = left ventricular

and

incremental

STUDY POPULATION AND DATA SYNTHESIS. The Cleve-

at admission, or baseline medication use information.
As in the derivation cohort, in the case of multiple

land Clinic Institutional Review Board approved this

admissions for a single patient, only the ﬁrst admis-

study. We identiﬁed 1,318 unique, consecutive pa-

sion was included. Clinical, demographic, imaging,

tients admitted to the internal medicine or cardiology

and laboratory data, and documented primary and

inpatient services at the Cleveland Clinic between

secondary diagnoses were reviewed from the elec-

July 28, 2008, and December 31, 2013, with a

tronic

medical

record.

Admission

chloride

was

discharge diagnosis of ADHF. We conﬁrmed the

deﬁned as the level on ﬁrst blood draw on presenta-

discharge diagnosis by performing a search of the

tion; discharge chloride was determined using the

International Classiﬁcation of Diseases-Ninth Revi-

blood draw on the day of discharge. All patients were

sion codes for acute or chronic HF (428.x). To further

followed until June 30, 2012, and death was veriﬁed

improve the speciﬁcity of selecting an established

by the Social Security Death Index.

chronic HF population, only patients with a docu-

STATISTICAL METHODS. Continuous variables were

mented prior cardiac implantable electronic device

expressed as median (interquartile range) and cate-

(implantable cardioverter-deﬁbrillator [ICD] or car-

gorical variables were expressed as percent. The

diac resynchronization therapy) were retained in the

Jonkheere-Terpstra and Cuzick methods were used to

registry. The presence of an ICD or cardiac resynch-

test trend across tertiles of admission chloride levels

ronization therapy device was conﬁrmed if there

for continuous and categorical variables, respectively

was a prior medical encounter caused by such a de-

(16). Spearman correlation coefﬁcients ( r) were used

vice (V45.02), radiological examination suggesting

to show correlations between continuous variables.

the presence of an ICD or cardiac resynchronization

Survival analyses were completed via the Kaplan-

therapy, electronic analysis of an ICD (including

Meier method and log-rank test to compare survival

interrogation, evaluation of generator status or pro-

curves across admission chloride tertiles. Cox pro-

gramming parameters, electrocardiographic analysis,

portional hazards models were used to examine the

or a wearable cardioverter-deﬁbrillator system), or

association between chloride levels and time to all-

procedure in which there was a prior insertion or

cause mortality after adjusting for potential con-

repositioning of an electrode lead for a single-

founders. Hazard ratios (HRs) and 95% conﬁdence

or dual-chamber pacing ICD and insertion of a pulse

intervals (CIs) for all-cause mortality were determined

generator.

for all covariates. Proportional hazard assumption vi-

Patients were excluded if they were not given a

olations were estimated by generalized linear regres-

loop diuretic during admission, did not have an active

sion of scaled Schoenfeld residuals on time. For

medication list, were <18 years of age, had prior heart

proportional hazard violations (p < 0.1), “within-

transplantation or mechanical circulatory assist de-

stratum” estimates were provided for models strati-

vice, or were on chronic dialysis therapy. Only the

ﬁed by categorical variables, and Heaviside functions

ﬁrst admission for a patient was included in the

were used to determine the time-dependency of risk

cohort if they were subsequently readmitted. Long-

for continuous variables. The model covariates were

term all-cause mortality was determined from the

selected a priori (based on previous prognostic reports

electronic medical record and validated, if possible,

in patients with HF and clinical experience) either

by the Social Security Death Index. All patients were

because of their prognostic relevance or their poten-

followed until December 31, 2013.

tial to confound the chloride-risk relationship. These

VALIDATION COHORT. Charts of consecutive admis-

included admission sodium, blood urea nitrogen,

sions to noninterventional cardiology or internal

length of stay (days), age (years), ischemic cardiomy-

medicine services at the Hospital of the University of

opathy, beta-blocker use, renin-angiotensin system

inhibitor use, and mineralocorticoid antagonist use

peptide) and indicators of end-organ function (hemoglobin and bilirubin). They were also inversely
related to length of stay in the hospital and net weight
change during admission.
CHLORIDE LEVELS AND ALL-CAUSE MORTALITY. The
Cleveland Clinic cohort of l ,3l 8 patients had 2,261
person-years of follow-up for all-cause mortality.
There were 359 deaths over a median follow-up
time of 1.47 (interquartile range: 0.51 to 2.68) years.
Kaplan-Meier survival estimates were different
across tertiles of admission chloride level (log-rank
p < 0.001 for all) (Central Illustration). There were
164, 127, and 68 deaths for tertiles 1 to 3, respectively.
Tertile 1 had a higher death incidence rate of
0.22 death/person-years compared with tertiles
2 and 3 with 0.14 and 0.10 death/person-years,
respectively.
Per the univariable and multivariable proportional
hazards models (Table 3), admission chloride levels
were inversely associated with mortality (p < 0.001).
Every unit increase in chloride was associated with an
-6% relative improvement in survival (HR per unit
change: 0.94; 95% CI: 0.92 to 0.95; p < 0.001).
Although admission sodium levels were also
inversely associated with mortality (HR per unit
change: 0.95; 95% CI: 0.93 to 0.97; p < 0.001),
admission chloride levels showed greater discrimination for mortality (C statistic: o.60; 95% CI: 0.57 to
o.64) than admission sodium levels (C statistic: 0.56;
95% CI: 0.53 to 0.59; p < 0.001). There was no

(17,18). The discrimination (C statistic) of the impact of

chloride levels on mortality was deter-mined as
previously described (19). Category-free netreclassification indexes and integrated discrimination improvement were calculated to further clarify
the incremental prognostic value of chloride (20).
Double-sided p values < 0.05 were considered
statistically significant. Statistical analyses were
performed using Stata version 13.1 software (StataCorp LP, College Station, Texas).
RESULTS

Baseline characteristics for the Cleveland Clinic and University of Pennsylvania cohorts are shown in Tables 1 and 2,
respectively. For the Cleveland Clinic cohort, admission chloride levels were normally distributed, with
median and mean admission chloride being 101 (interquartile range: 97 to 104) mEq/1 and 100 ± 6 mEq/1,

BASELINE CHARACTERISTICS.

respectively. As expected, admission chloride levels
were directly correlated to admission sodium levels (p
o.61; p < 0.001) and negatively correlated to
admission bicarbonate levels (p
0.39; p < 0.001).
Higher chloride levels were positively associated with
increasing LV ejection fraction, beta-blocker and
renin-angiotensin system-blocker use, and renal
dysfunction, but negatively associated with markers
of neurohormonal activation (blood urea nitrogen and
N-terminal pro-B-type natriuretic

TABLE 1 Baseline Cbaracteristlcs of the aeveland Clink Cohort
Admission CNoride (mEq/1)
Total (N

68.7 (59.1 to 77.2)

Age, yrs

Male

70.0

!scheme cardiomyopathy

LVEF, % (n

1,318)

3411
27 (19 to 45)

1,068)

<99 (n

456)

67 .9 (59.2to 76.2)
71.9

33.6
25 (15 to 40)

497)

6911
38.2

> 103 (n

365)

695 (60.1 to 78.2}
67.7
31.5

p Vllue•

0.09
0.19
0.64

25 (20 to45)

34 (20 to 50)

< 0.001

120 (105 to 137)

127 (113 to 144}

< 0.001

SBP, mm Hg
Beta blocker
RAS blocker

118 (105 to 137)

MRA

363
137 (135 to 140)

43.4
134 (131 to 137)

36.0
138 (136 to 149}

28.0
138 (138 to 142)

< 0.001

25 (22 to 27)

17 (24 to 30}

25 (23 to 27)

23 (21 to 25}

< 0.001

25 (18 to 34}

< 0.001

Sodlt.m, mEq/l
Bicarbonate, mEq/l
BUN, mg/dl
Creatinine, mg/dl
NT proBNP, pg/ml (n

84.9

80.3

88.3

86.0

0.01

59.2

52.2

62.2

63.8

< 0.001

27 (19 to 40)
1.28 (0.99 to 1.69)

481)

111 (102 to 128)

99 to 103 (n

68.4 (58.7 to 77 3}

4,817 (2,415 to 9,536}

31 (22 to 47)
1.33 (1.04 to 1.77)
5,793 (3,133 to 10,418)

< 0.001

27 (19 to 38)
1.29 (0.96 to 1.71)

1.20 (0.98 to 1.60}

0.004

4,268 (2,180 to 9,175)

4,684 (2,428 to 8,644)

0.044

11.7 (10.2 to 13.2}

113 (9. 7 to 12.7)

1.0 (0.6 to 1.5)

0.8 (0.5 to 1.3}

011 (05 to 1.1}

< 0.001

8.7 (S.O to 16.7)

9.7 (5.5 to 19.4}

9.0 (4.9 to 1711}

7.9 (4.9 to 14.1)

< 0.001

2.5 ( 6.0 to 0.1)

2.9 ( 6.8 to o.o)

211 ( 63 to 0.0)

15 ( 4.4 to 03)

< 0.001

Hemoglobin, g/dl
Total bilirubin, mg/dl

11.6 (10.1 to 13.1)

11.6 (10.2 to 13.2)

0.8 (0.5 to 13)

Length of stay, days

<\Weight during admission, kg

V.lues are median Onterquartlle range) or %. 'P val.u, for the Jond<heere-T"'tra or Cuzid< tests of trend.
BUN
blood Ul'N nitrog@l1; LVEF left ventnQllar 4'ection fraction; MRA rnineratoaw1ic:d antagonist; tfl'•proBNP
RAS reni.,..ngioten!in system; SBP systolic blood pressi.re.

0.003

N-tenninal pn,-B•type natril.l'etic p,¢de;

TABLE 2 Baseline Characteristics of the University of Pennsyl vania Cohort
Adnuion 0.l oride (mE.q/1)

Total (N

876)

62.9 (51.4 to 743)

Male

54.3

lschemic cardiomyopathy
LVEF,%

24.2

Age, yrs

27.S (15 to 475)

SBP, mm Hg

135 (115 to 158)

<101 (n

253)

101 ID 104 (n

262)

>104 (n

361)

p Value•

64.9 (53.8 to 74.8)

59.2 (483 to 72.7)

64.5 (523 to 75.6)

0.67

60.1

59.2

46.8

0.001

33.6

16.8

23.0

0.01

25 (15 to 45)

30 (15 to 47 5)

0.48

120 (102to 143)

138 (118 to 161)

145 (126 to 166)

< 0.001
0.10

27.5 (15 to 50)

Beta blocker

67.4

715

66.4

65.1

RAS blocker

61.2

60.9

63.7

59.6

0.67

MRA

15.1

225

14.1

10.5

< 0.001

139 (137 to 141)

141 (139 to 142)

< 0.001

139 (137 to 141)

136 (133 to 139)

Bicarbonate, mEq/l

25 (23 to 28)

28 (25 to 31)

26 (24 to 28)

24 (21 to 26)

< 0.001

BUN, mg/dl

22 (15 to 34)

30 (18 to48)

205 (15 to 27)

21 (14 to 33)

< 0.001

Creatinine, mg/dl

1.3 (1.0 to 1.7)

1.40 (1.0 to 1.8)

1.2 (1.0 to 15)

1.3 (1.0 to 1.7)

0.19
0.86

Sodium, mEq/l

1,314 (673 to 2,435)

1,372 (715 to 2,845)

1,241 (649 to 2,113)

1,319 (671 to 2,389)

Hemoglobin, g/dl

123 (10.7 to 13.6)

12.2 (10.6 to 13.7)

12.6 (11.0 to 13.9)

12.1 (10.6 to 135)

0.44

Total bilinbn , mg/dl

0.8 (05 to 1.4)

0.9 (0.6 to 1.7)

0.9 (0.5 to 1.4)

0.7 (0.4 to 1.0)

< 0.001

BNP, pg/ml

5 (4 to 8)

Length of stay, days
t.Weight during admission, kg

3.1 ( 5.9 to 0.8)

6 (4 to 9)
2.6 ( 5.9 to 0.7)

5 (4 to 8)

5 (4 to 7)

3.2 ( 6.4 to 0.9)

< 0.001

3.4 ( 5.4 to 0.7)

0.55

values are median (interquartile range) or%. •p value for the .lond<tieere•Terstra or Qaidc tests of trend.
BNP 11-l)pe natriln!lic peptide; olher -eviatlons as in Table I.

CENTRAL ILLUSTRATION Chloride in Acute Decompensated Heart Failure: Survival Est.i mates by Admission Chloride Levels

1.00

- a.so
0.75

ro

>
>

...:::,

Admission Chloride [mEq/ l]
- Tertile 1, <99
- Tertile 2, 99-103
Tertile 3, >103

V,

0.25
0.00

Log-rank, Chi-square 36.7, p <0.001

0
At-risk by Chloride Tertile
Tertile 1 456
Tertile 2 497
Tertile 3 365

2

3

235
319

148

243

147

82
95
78

1

Years

203

Grodin, J.L. et al. J Am Coll Cardiel. 2015: 66(6):659-66.

For t he Cleveland Clinic cohort, Kaplan Meier survival estimates significantly differed across tertiles of admission chloride level (log rank p < 0.001) , with
worse survival for lower admission chloride levels.

significant interaction between admission chloride
and sodium levels for mortality (p
0.19). KaplanMeier survival estimates stratified by admission
hypochloremia (chloride <96 mEq/1) and hyponatremia (sodium <134 mEq/1) are shown in Figure 1,
which graphically illustrates that chloride levels may
have a stronger prognostic role than sodium levels.
After multivariable adjustment, admission chloride
levels remained independently inversely associated
with mortality (HR per unit change: 0.93; 95% CT:
0.90 to 0.97; p < 0.001) (Figure 2). Mortality risk
increased with decreasing chloride levels below -96
mEq/1 and did not significantly differ at values >96
mEq/1. There was no increase in the overall C statistic
of the multivariable model with the addition of
chloride (o.68 vs. o.69; p
0.5). However, adding
chloride to the multivariable model did significantly
reclassify
risk
(integrated
discrimination
improvement, 10%; p < 0.001; category-free netreclassification indexes, 17.2%; p
0.006). With
additional adjustment for weight change and blood
urea nitrogen/creatinine ratio, admission chloride
levels remained significantly associated with
mortality (HR per unit change: 0.93; 95% CI: 0.90 to
0.97; p < 0.001).
However, after multivariable adjustment for
other variables including admission chloride levels,
admission sodium levels were not independently
associated with mortality (HR per unit change: 1.03;
95% CT: 0.99 to 1.07; p
0.18). Discharge chloride

TA8LE3 Unlvarlable and Multlvarlable Cox Proportional Hazards Models for Mortallty

M.. tlv.-

Univ-1,lo
HR

Cleveland Clinic Cohort
O,loride, mEq/l

95% 0

p Value

0.94

0.92 0.95

< 0.001 0.93•

0.95

0.93 0.97

< 0.001

Log BUN, mg/dl
259
lschemic cardiomyopathy 136

2.14 3.14

< 0.001

1.10 1.68

0.004
0.028

Sodium, mEq/l

Beta blocker

0.74

056 0.97

RAS blocker

0.77

0.63 0.95

SBP, mm Hg

0.991 0.986 0.995

Age, yrs

1.02

1.011.03

Bicarbonate, mEq/l

1.03

1.011.06

Length of stay, days

1.002 0.999 1.005

University of Pennsylvania Cohort
O,loride, mEq/l :S1 yr
0.93t

0.91 0.95

9 S% CI

p Valuo

0.90 0.97

<0.001

1.61 2.48

<0.001

HR

2.00•

0.015
< 0.001 0.993· 0.988 0.998 o.m
< 0.001 1.02•
1.011.03 <0.001
0.011
0.14
<00.001 0.95t

Chloride, mEq/l >1 yr

0.99t

0.971.02

0.56

Sodium, mEq/l

0.96

0.94 0.98

< 0.001

Log BUN, mg/dl
2.13
lschemic cardiomyopathy 1.48

1.83 2.48

< 0.001

1.211.81

< 0.001

Beta blocker

1.15

0.941.41

0.16

RAS blocker

0.96

0.79 1.15

0.63

MRA

1.14

0.88 1.47

SBP, mm Hg

0.994 0.991 0.997

< 0.001 0.996

Age, yrs

1.032 1.026 1.039

<0.001

Bicarbonat e, mEq/l

1.01

0.99 1.03

0.337

Length of stay, days

1.05

1.02 1.08

0.001

1.60

0.92 0.99

0.01

1.34 1.91

<0.001

0.33
0.992 0 .999

0.01

1.03

1.02 1.04

<0.001

1.03

1.00 1.07

0.04

'Within-stral\Jln estinate stratified by MRA use. tHRs rf$>crted b" both Heavi!ide functions in sane model.

Cl

a,nfidence interr.il; HR

har.ard ratio; other ~reviations as in Tallle L

p < 0.001) and adjusted analysis (HR per unit change:
level was significant when substituted for admission 0.95; 95% CT: 0.92 to 0.99; p 0.01). Additionally, the
chloride level (discharge sodium level was sub- adjusted association with admission sodium levels
stituted for admission sodium level) in the multivar- was not significant (HR per unit change: 0.99; 95% CI:
iable model for mortality (HR per unit change: 0.94;
95% CT: 0.92 to 0.97; p < 0.001) and is graphically
l'IOUAE 1 Survival Estimates Stratified by Admission
depicted in Figure 3.
Hypochloremla and Hyponatremla
To validate our present findings, we turned to an
independent acute HF cohort from the University of
1.00
Pennsylvania with longer follow-up (Table 3). Admission chloride distribution was comparable with our
0.75
study cohort (median: 103 [100 to 106) mEq/1; mean:
j
·s: 0.50
103 ± 6 mEq/l). Baseline characteristics of this validation cohort are presented in Table 2. Similar to the
Cleveland Clinic cohort, admission chloride levels
were directly correlated to admission sodium (p 0.54;
p < 0.001) and negatively correlated to admission bicarbonate levels (p ·0.49; p < 0.001). There were 453
deaths out of 876 patients with 3,038 person-years of
follow-up for all-cause mortality. In contrast to the
derivation cohort, admission chloride levels violated
the proportional hazards assumption (p > 0.1) and
were thus analyzed as a Heaviside function with time
stratified at 1 year. Admission chloride levels were
inversely associated with 1-year mortality in unadjusted (HR per unit change: 0.93; 95% CI: 0.91 to 0.95;

:5

VI

0.25

-

Chlaide <96 and Sodium <134
Chloride <96 and Sodium i 134

-

Chlaide >96 and Sodium <134
Chlondo >96 and Sodium s 134

Log-rank, chi-square 36.7 , p < .001

0.00
0

Years

2

3

At-risk by Chloride and Sodium Level [mEQ/1]
Chlondo <96 and Sodium <134
Chloride <96and Sodium i134
Chloride ~96 and Sodium <134

148

Chlondoe96andSodiume134

1000

86
84

97
61
71
838

91
55
67

791

85

54
66
766

Kaplan Meier survival curve estimates d.assified by levels of chloride (< or a:96 mEq/l} and
sodium(< or a:134 mEq/0 on admission demonstrate that chloride levels may provide a
stronger prognosis role than sodium levels.

"IOURE 2 Mortality Risk per Adjusted Admi ssion

Chloride Levels
4

a 95%CI
- Fitted ( UIVE!

-2

L,------,-----,-----,-----,
80
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100
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Admission Chloride [mEq/l]

A fitted curve was generated from residual estimates according
to admission chloride level at the Cleveland CUni c after multi
variable adjustment for sodium, length of stay, bicarbonate,
blood urea nitrogen, age, ischemic cardiomyopathy, and drug use

(beta blocker, renin angiotensin system blocker, and mineralo
corticoid antagonist). Cl

confidence interval.

0_96 to 1-03; p 0.58). Similar to the Cleveland Clinic
cohort, discharge chloride level was significant when
substituted for admission chloride level (discharge
sodium level was substituted for admission sodium
level) to the multivariable model for mortality (HR per
unit change: 0.97; 95% CI: 0.95 to 0.99; p 0.01).
DISCUSSION

In 2 contemporary cohorts of patients predominantly with systolic dysfunction hospitalized for

.,,ouRE 3 Mortality Risk per Adjusted Discharge

Chloride Levels
4

'o

iex

2

-2

a

95%CI

-

l=ltted Cuive

'-,-----,-----,-----,-----,
80
90
100
110
120
Discharge Cltorlde [mEq/\1

A fitted curve was generated from residual estimates according
to discharge chloride level at t he Cleveland CUnic after multi
variable adjustment for sodium, length of stay, bicarbonate,
blood urea nitrogen, age, ischemic cardiomyopathy, and drug use

(beta blocker, renin angiotensin system blocker, and mineralo
corticoid antagonist). Cl

confidence interval.

ADHF and electrolyte measures, we report several
key findings that highlight prognostic implications
of serum chloride. First, serum chloride levels were
independently and inversely associated with mortality after multivariable adjustment for other
prognostic factors including serum sodium concentration. Second, serum chloride levels modestly
enhanced mortality prediction compared with sodium levels. Furthermore, serum sodium levels
were no longer associated with mortality when
serum chloride levels were added to the multivariable model. Finally, although modestly correlated,
serum chloride and serum sodium levels had no
significant interaction for mortality prediction.
These findings highlight the prognostic implications
of serum chloride level in ADHF and suggest that it
provides stronger prognostic information than
serum sodium level. Further investigations into the
clinical relevance of hypochloremia in the setting of
acute HF are warranted.
The pathological role of chloride in HF is incompletely understood, in part because chloride levels
have been rarely documented in clinical trials or
registries. Chloride accounts for approximately onethird of the tonicity and two-thirds of all negative
charges in the plasma (21). Dietary sodium chloride
is the main source of chloride in the body and its
removal is facilitated by gastric, sweat, and renal
excretion. Serum chloride levels may represent the
downstream effects of adversely prognostic maladaptive neurohormonal, renal, and acid-base disturbances in HF. Indeed, mechanisms that reduce
sodium levels can similarly lower chloride levels
(22). These include: 1) the pathological impairment
of free water excretion resulting from increased
nonosmotic release of arginine vasopressin (23),
which is typically increased in patients with symptomatic HF (24,25); 2) the pleotropic effects of
excess angiotensin II on renal sodium and water
handling and neural thirst center activation (1); and
3) increased baroreceptor-mediated release of arginine vasopressin (24). All of these mechanisms are
directly stimulated in HF (26). As a result, lower
chloride levels may be dilutional in nature. Yet they
may also represent a state of electrolyte depletion,
especially when chloride is lower relative to sodium,
which can occur in the setting of diuretic-induced
salt wasting as chloride is excreted in the urine
while bicarbonate is retained to maintain electroneutrality (27). Making this distinction may have
clinical implications when administering decongestive therapies for acute HF (28).
Both sodium and chloride levels were prognostically similar in unadjusted, but not adjusted,

analyses, potentially suggesting a pathophysiolog-ical
difference in the 2 electrolytes. In the presence of HF,
the relative concentrations of sodium and chloride in
the plasma compartments can be Jow-ered
symmetrically or asymmetrically (29,30). This may
be related to the ability of the kidney to excrete these
electrolytes and modified by thera-peutic measures
(loop diuretics) and comorbid conditions. Chloride is a
buffer for cations, in-eluding acid and sodium, and
plays a major role in the ability of the kidney to
eliminate salt and water. Therefore, in contrast to
sodium, chloride has a stronger prognostic role
because it may play a broader homeostatic role.
Our finding that lower chloride levels during
admission were associated with higher mortality offers important insights into interpretation of electrolytes in ADHF. Our findings suggest that although
sodium levels are important, more robust prognostic
information can be inferred from serum chloride levels.
Although low sodium has consistently been shown to
be a strong predictor of short- and Jong-term morbidity
and mortality in patients with both systolic and
diastolic HF (7,u,13,31,32), there
was
little
mention of the impact of chloride on the interpretation
of sodium levels in these analyses. As our results
suggest, these previous results may have failed to take
into
account
serum
chloride
levels.
Prior evidence for the prognostic role of chloride is
sparse, and there is no formalized definition of
hypochlorernia in HF. Our observations highlight the
need to focus on better understanding of chloride
homeostasis and preserving it as a potential therapeutic consideration, particularly in the setting of
ADHF with extensive use of loop diuretics that
primarily inhibit the sodium-potassium-chloride
cotransporter leading to inevitable and excessive
chloride wasting.
results must be inter-preted
in the context of several limitations in our study
design. We cannot exclude the presence of selection
b ias for those undergoing evaluation and treatment for
ADHF at 2 tertiary care centers. How-ever, the external
validity of t hese findings is st-rengthened with the
addition of the validation cohort. These patients
largely had systolic dysfunc-tion with questionable
generalizability to an ADHF population with preserved
LV systolic function. Yet this also afforded an
opportunity for a diversity of pathology in a
contemporary cohort recorded by a modem electronic
medical record to be retrieved in a very efficient
manner. Our analysis also displayed a unique way of
identifying patients presenting

with ADHF and established HF based on the history
of an ICD. Data were Jacking regarding patient-level
decision making and resulting medication changes
and the impact they would have on changing chloride levels and prognosis. Similarly, the impact of
chloride levels on HF rehospitalizations could not be
determined. There was only a minority of patients
with serum chloride levels >107 mEq/1, and this
analysis was underpowered to determine increased
risk caused by hyperchloremia. To our knowledge,
however, therapies that increase serum chloride
concentrations, such as hypertonic saline, are rarely
used in ADHF populations, but the potential impact
of potassium supplementation with potassium chloride is unclear. Nevertheless, this large, wellpowered ADHF cohort confers a new perspective
on serum chloride levels and their impact on
prognosis.
CONCLUSIONS

Serum chloride levels measured during hospitalization for ADHF are independently and inversely assodated with Jong-term mortality. This association was
independent of, and added incremental prognostic
information to, serum sodium levels. These findings
highlight the clinical significance of chloride, a routinely measured electrolyte, in Jong-term prognostication for ADHF.
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